AKORN INC Form SC 13D/A September 27, 2006 UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D		
Under the Securities Exchange Act of 1934		
(Amendment No. 14)*		
Akorn, Inc.		
(Name of Issuer)		
Common Stock, no par value		
(Title of Class of Securities)		
009728 10 6		
(Cusip Number)		
John N. Kapoor	Сору	Thomas J. Murphy
EJ Financial Enterprises, Inc.	To:	McDermott, Will & Emery
225 E. Deerpath, Suite 250 Lake Forest, IL 60045		227 West Monroe Street
Lake Folest, IL 00045		Chicago, IL 60606
(Name, Address and Telephone Number of Person		
Authorized to Receive Notices and Communications)		
September 15, 2006		
(Date of Event Which Requires Filing of this Statement)		

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box //.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

#### SCHEDULE 13D

CUSIP No.	<u>009728 10 6</u>
-----------	--------------------

1	Names of Reporting John N. Kapoor Tr			es only):	
2	Check the Appropr (a) /X/ (b) //	iate Box i	if a Member of a Group (See Instructions):		
3	SEC Use Only:				
4	Source of Funds (S OO (See Item 3)	ee Instruc	ction):		
5	Check if Disclosure	e of Legal	Proceedings is Required Pursuant to Items 2(d) or 2(e):	//	
6	Citizenship or Plac Illinois	e of Orga	nization:		
N. I	COL	7	Sole Voting Power: 25,843,728		
Number of Benef Owne Each	icially	8	Shared Voting Power: -0-		
Repor Perso With		9	Sole Dispositive Power: 25,843,728		
		10	Shared Dispositive Power: -0-		
11 25,843,72		Benefici	ally Owned by Each Reporting Person:		
12	Check if the Aggre	gate Amo	ount in Row (11) Excludes Certain Shares (See Instructions):	//	

- Percent of Class Represented by Amount in Row (11): 31.98% based on 80,807,467 shares of common stock deemed outstanding
- 14 Type of Reporting Person (See Instructions): OO

## CUSIP No. <u>009728 10 6</u>

1	Names of Report John N. Kapoor		ns: I.R.S. Identification Nos. of Above Persons (	entities only):	
2	Check the Appr (a) /X (b) //		x if a Member of a Group (See Instructions):		
3	SEC Use Only:	SEC Use Only:			
4	Source of Funds	s (See Instr	uction):		
5	Check if Disclor Citizenship or P USA		gal Proceedings is Required Pursuant to Items 2(d) or 2(e): ganization:	//	
Bo O Ea Ro	ber of Shares eneficially wned by ach eporting	7 8 9	Sole Voting Power: 26,309,846  Shared Voting Power: 3,273,976  Sole Dispositive Power:		
	erson Tith	10	Shared Dispositive Power: 3,273,976		
11 29,58	Aggregate Amo	unt Benefi	cially Owned by Each Reporting Person:		
12	Check if the Ag	gregate An	nount in Row (11) Excludes Certain Shares (See Instructions)	/X/	
13	Percent of Class Represented by Amount in Row (11): 36.61% based on 80,807,467 shares of common stock deemed outstanding				
14	Type of Reporting Person (See Instructions):				

## CUSIP No. <u>009728 10 6</u>

1	Names of Reporting Persons: EJ Financial/Akorn Management, L.P.			I.R.S. Identification Nos. of Above Persons (entities only):		
2	Check the Appropriate Box if a Member of a Group (See Instructions):  (a) /X/ (b) //					
3	SEC Use Only:					
4	Source of Funds (See Instruction): OO					
5	Check if Disclosure	of Legal	Proceedings is Required Pursuant to Items 2(d) or 2(e):	//		
6	Citizenship or Place of Organization: Illinois					
	0.01	7	Sole Voting Power: -0-			
Number of Shares Beneficially Owned by Each		8	Shared Voting Power: 3,273,976			
Repor Person With		9	Sole Dispositive Power: -0-			
		10	Shared Dispositive Power: 3,273,976			
11 3,273,976		Beneficia	ly Owned by Each Reporting Person:			
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):					
13	Percent of Class Represented by Amount in Row (11): 4.14% based on 79,140,467 shares of common stock deemed outstanding					
14	Type of Reporting Person (See Instructions) PN					

## CUSIP No. <u>009728 10 6</u>

1	Names of Reporting Persons: Pharma Nevada, Inc.		is: I.R.S. Identification Nos. of Above Persons (er	I.R.S. Identification Nos. of Above Persons (entities only):		
2	Check the Appro (a) /X/ (b) //		a if a Member of a Group (See Instructions):			
3	SEC Use Only:					
4	Source of Funds OO	(See Instru	action):			
5	Check if Disclos	ure of Leg	al Proceedings is Required Pursuant to Items 2(d) or 2(e):	//		
6	Citizenship or Pl Illinois	ace of Org	anization:			
<b>N</b> T 1	c qi	7	Sole Voting Power: -0-			
Number of Shares Beneficially Owned by Each		8	Shared Voting Power: 3,273,976			
Re	porting rson	9	Sole Dispositive Power: -0-			
		10	Shared Dispositive Power: 3,273,976			
11 3,273,		ınt Benefic	cially Owned by Each Reporting Person:			
12	Check if the Agg	regate Am	nount in Row (11) Excludes Certain Shares (See Instructions):	//		
13			ed by Amount in Row (11): 7 shares of common stock deemed outstanding			
14	Type of Reportin	ng Person (	See Instructions)			

This Amendment No. 14 (the Amendment ) to Schedule 13D is being filed to disclose that, on September 15, 2006 the John N. Kapoor Trust dated September 20, 1989 (the Trust ) exercised certain warrants to purchase 4,670,047 shares of common stock of Akorn, Inc. ( Akorn ). In connection with the exercise of the warrants, the Trust elected to satisfy the exercise price by directing Akorn to withhold from the shares otherwise issuable pursuant to the warrants 1,267,0697 shares having a value on the date of the exercise equal to the exercise price. On March 17, 2006, Mr. Kapoor exercised an option to purchase 500,000 shares of common stock, and he elected to satisfy the exercise price by directing Akorn to withhold 243,506 shares having value on the date of exercise equal to the exercise price.

This Amendment is filed jointly by (i) the Trust, of which John N. Kapoor is trustee and sole beneficiary, (ii) John N. Kapoor, (iii) EJ Financial/Akorn Management, L.P., a Delaware limited partnership ( EJ/Akorn ) of which Pharma Nevada, Inc. is the managing general partner, and (iv) Pharma Nevada, Inc., a Nevada corporation wholly owned by John N. Kapoor of which John N. Kapoor serves as the president and chairman of the board of directors (collectively, the Reporting Persons ).

#### Item 4. Purpose of Transaction

The Reporting Persons have acquired the Akorn securities as an investment and intend to continue to review Akorn s business affairs and general economic and industry conditions. Based upon such review, the Reporting Persons, will, on an on-going basis, evaluate various alternative courses of action including additional capital investments in Akorn. Alternatively, the Reporting Persons may sell all or a portion of their holdings in Akorn in the open market, subject to the requirements of Rule 144 or as otherwise permitted.

#### Item 5. Interest In Securities of the Issuer

(a) As of the date hereof:
(i) John N. Kapoor beneficially owns (a) 402,518 Shares representing 0.498% of the Shares outstanding, (b) 25,843,728 Shares representing 31.98% of the Shares outstanding through the Trust, of which he is the sole trustee, (c) 3,273,976 Shares representing 4.14% of Shares outstanding through EJ/Akorn; and (d) 63,600 Shares representing 0.079% of the Shares outstanding in his capacity as trustee of four trusts established for the benefit of the children of John Kapoor and Editha Kapoor.
In accordance with the requirements for determining beneficial ownership of a class of securities pursuant to Schedule 13D, the above Akorn share ownership percentages are calculated assuming the conversion of all convertible securities and exercise of all warrants held by the Reporting Persons, but not of all outstanding convertible securities, warrants and options of Akorn eligible for conversion or exercise. If the above percentages were calculated on a fully diluted basis, after the conversion of all convertible securities and exercise of all warrants of Akorn, John N. Kapoor s ownership percentage of Akorn common stock would be reduced to approximately 32.37%.
(ii) the Trust beneficially owns (a) 24,176,728 Shares representing 29.919% of the Shares outstanding and (b) 1,667,000 representing warrants, convertible debt and the right to convert interest accrued (2.063%).
(iii) EJ/Akorn owns 3,273,976 Shares representing 4.14% of the Shares outstanding; and
(iv) Pharma Nevada, Inc. owns 3,273,976 Shares representing 4.14% of the Shares outstanding through EJ/Akorn.
(b) John N. Kapoor has sole voting and dispositive power over 26,309,846 Shares (comprised of the Shares and warrants held by the Trust) and shared dispositive and voting power over 3,273,976 Shares (comprised of Shares held by EJ/Akorn). The Trust, acting through its trustee, has sole voting and dispositive power over 24,176,728 Shares and does not share voting power or dispositive power over any other Shares. EJ/Akorn, acting through its managing general partner, has shared voting and dispositive power over 3,273,976 Shares and does not share voting power or dispositive power over any other Shares. Pharma Nevada, Inc. has shared voting and dispositive power over 3,273,976 Shares held through EJ/Akorn and does not share voting power or dispositive power over any other Shares.
(c) Inapplicable
(d) Inapplicable.
(e) Inapplicable.

Material to Be Filed as Exhibits

Item 7.

The following Exhibits are filed with this Amendment:

1. Agreement required by Rule 13d-1(k)(1)(iii).

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 27, 2006 /s/ John N. Kapoor John N. Kapoor

September 27, 2006 EJ FINANCIAL/AKORN MANAGEMENT, L.P.

By: Pharma Nevada, Inc., Managing General Partner

> /s/ John N. Kapoor John N. Kapoor, President

September 27, 2006 Pharma Nevada, Inc.

By: /s/ John N. Kapoor

John N. Kapoor, President

September 27, 2006 John N. Kapoor Trust

dtd 9/20/89

/s/ John N. Kapoor John N. Kapoor as Trustee

EXHIBIT A		
AGREEMENT		
ТО		
JOINTLY FILE SCHEDULE 13D		
		es this Schedule 13D and any future amendment thereto reporting each of the
undersigned's ownership of securities of Akorn, Inc., and hereby affirm the	iat such s	Schedule 13D is being filed on behalf of each of the undersigned.
September 27, 2006		/s/ John N. Kapoor
		John N. Kapoor
September 27, 2006	EJ FIN	NANCIAL/AKORN MANAGEMENT, L.P.
		Pharma Nevada, Inc.,
	By:	Managing General Partner
		/s/ John N. Kapoor
		John N. Kapoor, President
September 27, 2006	Pharm	a Nevada, Inc.
	By:	/s/ John N. Kapoor
	Бу.	John N. Kapoor, President
September 27, 2006		N. Kapoor Trust
	dtd 9/2	20/89
	By:	/s/ John N. Kapoor

John N. Kapoor as Trustee